Zurcher Kantonalbank Zurich Cantonalbank Grows Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Moderna, Inc. (NASDAQ:MRNA) by 75.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 117,636 shares of the company’s stock after buying an additional 50,504 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Moderna were worth $11,699,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Everence Capital Management Inc. boosted its position in shares of Moderna by 14.3% in the 4th quarter. Everence Capital Management Inc. now owns 9,330 shares of the company’s stock worth $928,000 after buying an additional 1,170 shares in the last quarter. SVB Wealth LLC purchased a new position in Moderna in the 4th quarter valued at about $330,000. Mackenzie Financial Corp lifted its holdings in Moderna by 69.0% in the 4th quarter. Mackenzie Financial Corp now owns 115,007 shares of the company’s stock valued at $11,437,000 after purchasing an additional 46,964 shares in the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors lifted its holdings in Moderna by 6.5% in the 4th quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 2,459 shares of the company’s stock valued at $245,000 after purchasing an additional 151 shares in the last quarter. Finally, Conning Inc. purchased a new position in Moderna in the 4th quarter valued at about $207,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Price Performance

Moderna stock opened at $101.41 on Friday. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. The stock has a 50 day moving average of $100.63 and a 200-day moving average of $93.64. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $144.43.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, beating the consensus estimate of ($0.78) by $1.33. The company had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The business’s revenue was down 44.9% on a year-over-year basis. During the same period in the prior year, the business posted $3.61 EPS. Equities analysts expect that Moderna, Inc. will post -7.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on MRNA. Jefferies Financial Group restated a “buy” rating and issued a $125.00 target price on shares of Moderna in a report on Tuesday, April 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $125.00 price objective on shares of Moderna in a research note on Thursday, March 28th. Oppenheimer raised shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective for the company in a research note on Tuesday, January 2nd. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Thursday, April 11th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $126.49.

Insider Activity

In other news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $109.06, for a total transaction of $1,635,900.00. Following the completion of the transaction, the director now directly owns 2,101,931 shares in the company, valued at approximately $229,236,594.86. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $109.06, for a total transaction of $1,635,900.00. Following the transaction, the director now directly owns 2,101,931 shares in the company, valued at $229,236,594.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James M. Mock sold 647 shares of the firm’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $61,186.79. Following the transaction, the chief financial officer now owns 4,300 shares in the company, valued at $406,651. The disclosure for this sale can be found here. In the last three months, insiders sold 109,954 shares of company stock worth $11,533,976. 15.70% of the stock is currently owned by insiders.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.